<DOC>
	<DOCNO>NCT01034410</DOCNO>
	<brief_summary>This open label randomize control phase II study AS1411 combine Cytarabine treatment patient primary refractory relapse acute myeloid leukemia .</brief_summary>
	<brief_title>A Study AS1411 Combined With Cytarabine Treatment Patients With Primary Refractory Relapsed Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>Diagnosis AML define World Health Organization ( WHO ) classification ( Vardiman 2009 ) Primary refractory AML ( defined failure achieve CR CRi therapy curative intent ) AML first relapse ECOG Performance status 0 , 1 2 Age &gt; 18 &lt; 70 year For patient present primary refractory AML , &gt; 20 % blast baseline bone marrow assessment For patient present relapsed AML , &gt; 5 % blast baseline bone marrow assessment An initial diagnosis acute promyelocytic leukemia ( defined FrenchAmericanBritish criterion ( Bennett 1976 ) ) Secondary AML , define AML evolve antecedent hematological disorder prior exposure leukemogenic therapy agent Clinically active CNS leukemia Previously receive total cumulative dose cytarabine &gt; 6g/m2 last 6 month Previously receive &gt; 1 induction regimen ( Defined 1 2 cycle drug drug combination administer remission induction therapy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>AS1411</keyword>
	<keyword>AML</keyword>
	<keyword>relapse</keyword>
	<keyword>refractory</keyword>
	<keyword>aptamer</keyword>
	<keyword>nucleolin</keyword>
</DOC>